Recent advances in the clinical development of immune checkpoint blockade therapy
- 14 June 2019
- journal article
- review article
- Published by Springer Nature in Cellular Oncology
- Vol. 42 (5) , 609-626
Abstract
The discovery of immune checkpoint proteins and the mechanisms by which cancer cells utilize them to evade the immune system has transformed our approach to cancer immunotherapy. Checkpoint blockade antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligands such as programmed cell death ligand 1 (PD-L1) have already revolutionized the treatment of multiple types of cancer and have significantly improved treatment and survival outcomes of patients affected by these malignancies.Keywords
This publication has 152 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsNature Reviews Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1Journal of Experimental Medicine, 2009
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C TerminusJournal of Biological Chemistry, 2001